SARS相关冠状病毒M蛋白基因核酸疫苗的实验研究
发布时间：2018-07-18 09:09
【摘要】：SARS (Severe Acute Respiratory Syndrome)是一种传染性强、病死率高、严重危害人民生命健康的传染病。世界卫生组织于2003年4月6日宣布引起SARS的病原体是一种新的病毒,属于冠状病毒家族,称为SARS相关冠状病毒(SAPS-Associated coronavirus, SARS-CoV)。SARS-CoV表现出许多不同于冠状病毒的特性,为冠状病毒中一个新的分支。目前,病毒性疾病尚无特效治疗方法,对于SARS也是一样。所以,控制SARS的最好办法是预防,而疫苗的开发则是建立有效防范措施的关键环节。DNA疫苗是继病原体疫苗、亚单位疫苗之后的第三代疫苗,具有许多的优越性。所以本研究选择了SARS病毒DNA疫苗这一方向,以SARS-CoV主要结构蛋白之一——M蛋白基因作为研究对象。构建针对SARS-CoVM蛋白基因的重组核酸疫苗,观察其免疫小鼠后机体的特异性免疫应答的情况,探讨其作为抗SARS-CoV疫苗的可能性。 本研究由两部分组成: 第一部分为 SARS-CoV M蛋白基因重组核酸疫苗的构建。从GenBank上获取SARS病毒株SIN2774的M蛋白基因序列,使用引物设计软件Primer Premier 5.0进行引物设计,从中选择最佳引物,并在引物5’端分别添加真核表达质粒pcDNA3.1(+)多克隆位点中所包含的EcoRⅠ和Xho Ⅰ酶切位点及保护碱基,以从新加坡获得的SIN2774 cDNA为模
[Abstract]:SARS (severe Acute Respiratory Syndrome) is a kind of infectious disease with high mortality and serious harm to people's life and health. The World Health Organization (WHO) announced on April 6, 2003 that the pathogen causing SARS is a new virus, belonging to the coronavirus family, called SARS-associated coronavirus (SARS-CoV). SARS-CoV shows many characteristics different from coronavirus. It is a new branch of coronavirus. At present, there is no special treatment for viral diseases, and the same is true for SARS. Therefore, the best way to control SARS is prevention, and the development of vaccine is the key link to establish effective preventive measures. DNA vaccine is the third generation vaccine after pathogen vaccine and subunit vaccine, which has many advantages. In this study, we chose the SARS-CoV DNA vaccine as the direction, and took M protein gene, one of the main structural proteins of SARS-CoV, as the research object. The recombinant nucleic acid vaccine against SARS-CoVM protein gene was constructed to observe the specific immune response of mice after immunization, and to explore the possibility of the recombinant nucleic acid vaccine as an anti-SARS-CoV vaccine. This study consists of two parts: the first part is the construction of SARS-CoV M gene recombinant nucleic acid vaccine. The M protein gene sequence of SARS virus strain SIN2774 was obtained from GenBank. Primer design software Primer Premier 5.0 was used to design the primers, and the best primers were selected. The eukaryotic expression plasmids pcDNA3.1 () polyclonal sites containing Ecor 鈪，
本文编号：2131435
[Abstract]:SARS (severe Acute Respiratory Syndrome) is a kind of infectious disease with high mortality and serious harm to people's life and health. The World Health Organization (WHO) announced on April 6, 2003 that the pathogen causing SARS is a new virus, belonging to the coronavirus family, called SARS-associated coronavirus (SARS-CoV). SARS-CoV shows many characteristics different from coronavirus. It is a new branch of coronavirus. At present, there is no special treatment for viral diseases, and the same is true for SARS. Therefore, the best way to control SARS is prevention, and the development of vaccine is the key link to establish effective preventive measures. DNA vaccine is the third generation vaccine after pathogen vaccine and subunit vaccine, which has many advantages. In this study, we chose the SARS-CoV DNA vaccine as the direction, and took M protein gene, one of the main structural proteins of SARS-CoV, as the research object. The recombinant nucleic acid vaccine against SARS-CoVM protein gene was constructed to observe the specific immune response of mice after immunization, and to explore the possibility of the recombinant nucleic acid vaccine as an anti-SARS-CoV vaccine. This study consists of two parts: the first part is the construction of SARS-CoV M gene recombinant nucleic acid vaccine. The M protein gene sequence of SARS virus strain SIN2774 was obtained from GenBank. Primer design software Primer Premier 5.0 was used to design the primers, and the best primers were selected. The eukaryotic expression plasmids pcDNA3.1 () polyclonal sites containing Ecor 鈪，
本文编号：2131435
本文链接：https://www.wllwen.com/yixuelunwen/binglixuelunwen/2131435.html
最近更新
教材专著
